Rodabe N. Amaria

Sep 6, 2024 | digitalcommons.library.tmc.edu | Rodabe N. Amaria |Anne T. Knisely |David Vining |Scott Kopetz

BACKGROUND: Tumor-infiltrating lymphocyte (TIL) therapy has shown efficacy in metastatic melanoma, non-small cell lung cancer, and other solid tumors. Our preclinical work demonstrated more robust CD8 predominant TIL production when agonistic anti-4-1BB and CD3 antibodies were used in early ex vivo TIL culture. METHODS: Patients with treatment-refractory metastatic colorectal (CRC), pancreatic (PDAC) and ovarian (OVCA) cancers were eligible.

Jul 26, 2024 | targetedonc.com | Rodabe N. Amaria

OBX-115 is a novel engineered tumor infiltrating lymphocyte (TIL) therapy designed to treat patients with checkpoint inhibitor-resistant metastatic melanoma. Unlike traditional TIL therapies that require toxic high-dose interleukin-2 (IL2), OBX-115 incorporates a regulated IL15 system, eliminating the need for this harmful cytokine. Early results from a phase 1 study (NCT05470283) are encouraging. OBX-115 was well-tolerated with no severe adverse effects.

Feb 1, 2024 | jitc.bmj.com | Rodabe N. Amaria |Anne T. Knisely |David Vining |Scott Kopetz

MethodsMale and female patients between the ages of 18 and 70 years old with recurrent/refractory high-grade non-mucinous OVCA, CRC, or oligometastatic PDAC with an area of tumor amenable to excisional biopsy were considered for enrollment. For the OVCA cohort, patients were required to have failed at least two prior lines of chemotherapy or have platinum-resistant disease.